Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 and 2 Study of Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Malignant Glial Tumors of the Brain

NCT00671710 is registered in ClinicalTrials.gov with Advocate Hospital System as lead sponsor.

NCT NCT00671710
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00671710 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 and 2 Study of Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Malignant Glial Tumors of the Brain
Lead sponsor
Advocate Hospital System
Phase
Phase 1
Overall status
Completed
Start date
April 30, 2008
Completion date
November 30, 2010
Enrollment
26 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

brain tumors